Opendata, web and dolomites

HD4HF

Heart Damper: a revolutionary device for Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HD4HF project word cloud

Explore the words cloud of the HD4HF project. It provides you a very rough idea of what is the project "HD4HF" about.

owned    upwards    ease    respect    billion    public    issue    80    people    symptoms    tah    life    fitted    total    implanted    productivity    12    therapies    innovation    million    feasibility    assist    sufficient    procedure    surgical    cardiac    cure    stably    independently    penetration    38    staggering    impossible    contractile    ventricle    hd    healthcare    supports    protected    hf    age    systolic    transplantation    actual    rare    65    eucardia    implantable    individual    risk    time    segment    apart    residual    artificial    moves    stage    longer    patent    external    device    vad    intended    granted    damper    transapical    rejection    invasive    introduction    minimally    epidemic    quality    community    designed    15    once    reducing    pharmacological    quick    expectancy    economic    treatments    left    give    sources    patient    sme    health    patients    household    family    energy    worldwide    heart    instrument    countries    market    cacapacity    alone    social    2030    viability    ventricular    solution    innovative    treat    inevitably   

Project "HD4HF" data sheet

The following table provides information about the project.

Coordinator
EUCARDIA SRL 

Organization address
address: VIA GIACOMO LEOPARDI 7
city: MILANO
postcode: 20123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUCARDIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

This project supports the market introduction of the Heart Damper (HD), a very innovative implantable cardiac device, intended to provide a simple, quick and cost-effective solution to treat patients affected by systolic heart failure.

Heart Failure (HF) is a growing epidemic and a major public health issue: only in EU and US it affects today about 15 million people, with an expected growth of about 38% by 2030. 2 million of these patients are affected by advanced heart failure: a phase in which the pharmacological therapies alone are no longer sufficient to manage the symptoms. Late stage treatments, such as Ventricular Assist Device (VAD) or Total Artificial Heart (TAH) are indeed inevitably associated with high risk of rejection and low quality of life. HF has no actual cure apart from heart transplantation, which is very rare and impossible for people over 65 (80% of HF patients). In addition, HF has a significant social cost, as it doesn’t affect only the individual patient, but also his family and his community. In the US, for example, the costs related to the loss of work and household productivity are estimated at $ 8.2 billion/year (by 2030, $12.3 billion/year).

The Heart Damper, a minimally invasive cardiac device, will make it possible to give patients a longer and better life expectancy, independently from their age, at the same time reducing the staggering associated healthcare costs. Designed to be stably fitted into the left ventricle by a simple transapical surgical procedure, once implanted it moves upwards exploiting the residual contractile cacapacity of the heart, without any need of external energy sources. The device is protected by a patent fully owned by Eucardia, which has been granted in Europe, US and other major countries worldwide.

The SME 1 Instrument will enable Eucardia to assess in detail the technical feasibility and economic viability of its innovation, in order to ease HD market penetration, in respect of HF market segment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HD4HF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HD4HF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

GUARDIAN (2020)

Eco-friendly smart doors for non-residential building fire protection

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More